When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's "complete response" letter for kidney transplant drug does not require that Bristol-Myers Squibb do additional clinical trials, but firm must provide updates from ongoing study before approval.
You may also be interested in...
Bristol's Kidney Transplant Drug Belatacept Finally Approved
Large patient registry will help keep tabs on risk for post-transplant lymphoproliferative disorder.
Bristol's Kidney Transplant Drug Belatacept Finally Approved
Large patient registry will help keep tabs on risk for post-transplant lymphoproliferative disorder.
Bristol's Belatacept Could See Approval In Second Quarter After GMP Delay
The kidney transplant drug Nulojix (belatacept) is finished at the plant in Puerto Rico that won't be inspection-ready until the end of the year following a August warning letter.